PTX Target Price Revision – H.C Wainwright & Co
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
To stay up to date with Prescient Therapeutics news and events, please register your details.